Colgate-Palmolive (CL) Reports Q1 Earnings: What Key Metrics Have to Say
Werte in diesem Artikel
Colgate-Palmolive (CL) reported $4.91 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3%. EPS of $0.91 for the same period compares to $0.86 a year ago.The reported revenue represents a surprise of +1.15% over the Zacks Consensus Estimate of $4.86 billion. With the consensus EPS estimate being $0.86, the EPS surprise was +5.81%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Oral, Personal and Home Care- North America: $998 million versus $1 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +0.1% change. Net Sales- Oral, Personal and Home Care- Latin America: $1.14 billion compared to the $1.09 billion average estimate based on six analysts. The reported number represents a change of -8.8% year over year. Net Sales- Oral, Personal and Home Care- Africa/Eurasia: $271 million compared to the $273.66 million average estimate based on six analysts. The reported number represents a change of -1.8% year over year. Net Sales- Oral, Personal and Home Care- Europe: $690 million versus the six-analyst average estimate of $674.15 million. The reported number represents a year-over-year change of -3%. Net Sales- Oral, Personal and Home Care- Asia Pacific: $690 million versus the six-analyst average estimate of $727.36 million. The reported number represents a year-over-year change of -5.1%. Net Sales- Pet Nutrition: $1.12 billion versus the six-analyst average estimate of $1.09 billion. The reported number represents a year-over-year change of +1.5%. Net Sales- Total Oral, Personal and Home Care: $3.79 billion versus the six-analyst average estimate of $3.77 billion. The reported number represents a year-over-year change of -4.3%. Operating profit- Total Oral, Personal and Home Care: $971 million versus $1.01 billion estimated by four analysts on average. Operating profit- Corporate: -$153 million versus the four-analyst average estimate of -$182.49 million. Operating profit- Pet Nutrition: $258 million compared to the $239.30 million average estimate based on four analysts. View all Key Company Metrics for Colgate-Palmolive here>>>Shares of Colgate-Palmolive have returned -0.5% over the past month versus the Zacks S&P 500 composite's -4.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Colgate-Palmolive Company (CL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Colgate-Palmolive und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Colgate-Palmolive
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Colgate-Palmolive
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Colgate-Palmolive Co.
Analysen zu Colgate-Palmolive Co.
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2017 | Colgate-Palmolive Hold | Deutsche Bank AG | |
30.01.2017 | Colgate-Palmolive Hold | Stifel, Nicolaus & Co., Inc. | |
28.10.2016 | Colgate-Palmolive Neutral | B. Riley & Co., LLC | |
28.10.2016 | Colgate-Palmolive Neutral | UBS AG | |
29.04.2016 | Colgate-Palmolive Neutral | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
30.01.2017 | Colgate-Palmolive Hold | Stifel, Nicolaus & Co., Inc. | |
17.10.2014 | Colgate-Palmolive Market Perform | BMO Capital Markets | |
11.12.2012 | Colgate-Palmolive overweight | HSBC | |
26.11.2012 | Colgate-Palmolive kaufen | Die Actien-Börse | |
18.10.2011 | Colgate-Palmolive overweight | Morgan Stanley |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2017 | Colgate-Palmolive Hold | Deutsche Bank AG | |
28.10.2016 | Colgate-Palmolive Neutral | B. Riley & Co., LLC | |
28.10.2016 | Colgate-Palmolive Neutral | UBS AG | |
29.04.2016 | Colgate-Palmolive Neutral | UBS AG | |
04.01.2016 | Colgate-Palmolive Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
05.01.2005 | Update Colgate-Palmolive Co.: Sell | Banc of America Sec. | |
05.01.2005 | Update Colgate-Palmolive Co.: Sell | Banc of America Sec. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Colgate-Palmolive Co. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen